XERS
NASDAQXeris Biopharma Holdings Inc.
Price$8.80+0.05 (+0.57%)
01:30 PM07:45 PM
News · 26 weeks55-27%
2026-01-182026-07-12
Mix3490d
- SEC Filings14(41%)
- Insider13(38%)
- Other4(12%)
- Earnings2(6%)
- Leadership1(3%)
Latest news
25 items- SECXeris Biopharma Holdings Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Other Events8-K - Xeris Biopharma Holdings, Inc. (0001867096) (Filer)
- INSIDEROfficer Pieper Steven sold $383,176 worth of shares (45,000 units at $8.52) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 1,366,053 units (SEC Form 4)4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)
- PRCORRECTING and REPLACING Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)Please replace the release issued earlier today with the following corrected version that provides additional information regarding the inducement grants. The corrected release reads: XERIS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4) Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on July 1, 2026, the Compensation Committee of Xeris’ Board of Directors granted a non-qualified stock option and restricted stock units for an aggregate of 221,323 shares of its common stock to 47 new employee
- INSIDERDirector Kreher Nerissa was granted 33,582 shares (SEC Form 4)4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)
- INSIDERSEC Form 3 filed by new insider Kreher Nerissa3 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)
- INSIDEROfficer Mcculloch Kevin sold $722,511 worth of shares (90,000 units at $8.03) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 1,691,126 units (SEC Form 4)4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)
- INSIDEROfficer Hecht Beth sold $133,860 worth of shares (16,666 units at $8.03) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 1,161,128 units (SEC Form 4)4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)
- PRXeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on July 1, 2026, the Compensation Committee of Xeris’ Board of Directors granted restricted stock units for an aggregate of 221,323 shares of its common stock to 47 new employees under Xeris’ Inducement Equity Plan. Xeris’ Inducement Equity Plan is used exclusively for the grant of equity awards to individuals who were not previously employed by Xeris or one of its subsidiaries as an inducement material to such individual's entering into employment with Xeris or on
- SECSEC Form 144 filed by Xeris Biopharma Holdings Inc.144 - Xeris Biopharma Holdings, Inc. (0001867096) (Subject)
- SECXeris Biopharma Holdings Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Xeris Biopharma Holdings, Inc. (0001867096) (Filer)
- PRXeris Announces Updates to Its Board of DirectorsChief Executive Officer John Shannon named Chair of the Board Marla Persky to transition to Lead Independent Director of the Board Board appoints Nerissa Kreher, M.D., effective July 1, 2026 Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that its Board of Directors appointed John Shannon to Chair of the Board, in addition to his role as Chief Executive Officer, effective July 1, 2026. Mr. Shannon succeeds Marla Persky, who will remain on the Board as Lead Independent Director. The Company also announced the appo
- PRXeris Biopharma Announces Notice of Allowance From U.S. Patent and Trademark Office for New Patent Covering KEVEYIS®Patent expected to provide intellectual property protection for Keveyis through 2039 Reinforces Xeris' commitment to the primary periodic paralysis community and the patients who rely on Keveyis Xeris Pharmaceuticals, Inc., a wholly owned subsidiary of Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, announced that today the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance with respect to U.S. Patent Application No. 17/151,405, entitled "Compositions and Methods of Use." The allowed claims in this applic
- SECXeris Biopharma Holdings Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits8-K - Xeris Biopharma Holdings, Inc. (0001867096) (Filer)
- PRXeris Biopharma Announces Private Exchange of Convertible NotesEliminates approximately $23 million of debt, resulting in approximately $2 million in annual interest savings Principal to be paid in cash, remainder in common stock Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that it has entered into separate, privately negotiated exchange agreements with certain holders of its 8.00% Convertible Senior Notes due 2028 (the "Notes"). Pursuant to the exchange agreements, Xeris has agreed, subject to customary closing conditions, to retire approximately $23 million aggregate princi
- INSIDERDirector Kong Garheng was granted 24,193 shares, increasing direct ownership by 11% to 238,337 units (SEC Form 4)4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)
- INSIDERDirector Persky Marla sold $91,433 worth of shares (15,500 units at $5.90) as part of a pre-agreed trading plan and was granted 24,193 shares, increasing direct ownership by 6% to 150,693 units (SEC Form 4)4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)
- INSIDERDirector Halkuff Dawn sold $121,886 worth of shares (20,000 units at $6.09) as part of a pre-agreed trading plan and was granted 24,193 shares, increasing direct ownership by 4% to 119,193 units (SEC Form 4)4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)
- INSIDERDirector Bormann-Kennedy Barbara-Jean Anne sold $97,507 worth of shares (16,000 units at $6.09) as part of a pre-agreed trading plan and was granted 24,193 shares, increasing direct ownership by 6% to 150,693 units (SEC Form 4)4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)
- INSIDERDirector Johnson John sold $91,422 worth of shares (15,000 units at $6.09) as part of a pre-agreed trading plan and was granted 24,193 shares, increasing direct ownership by 1% to 707,276 units (SEC Form 4)4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)
- INSIDERDirector Brady James Aloysius was granted 24,193 shares, increasing direct ownership by 27% to 113,359 units (SEC Form 4)4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)
- SECXeris Biopharma Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Xeris Biopharma Holdings, Inc. (0001867096) (Filer)
- SECSEC Form 144 filed by Xeris Biopharma Holdings Inc.144 - Xeris Biopharma Holdings, Inc. (0001867096) (Subject)
- SECSEC Form 144 filed by Xeris Biopharma Holdings Inc.144 - Xeris Biopharma Holdings, Inc. (0001867096) (Subject)
- SECSEC Form 144 filed by Xeris Biopharma Holdings Inc.144 - Xeris Biopharma Holdings, Inc. (0001867096) (Subject)
- SECSEC Form 144 filed by Xeris Biopharma Holdings Inc.144 - Xeris Biopharma Holdings, Inc. (0001867096) (Subject)
XERS FAQ
7 questionsWhat does Xeris Biopharma Holdings Inc. do?
Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technology platforms allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, small molecules, and proteins using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps. The company's lead product candidate is Gvoke HypoPen for the treatment of severe hypoglycemia, a potentially life-threatening condition in...Where does XERS stock trade?
Xeris Biopharma Holdings Inc. (XERS) is listed on NASDAQ.What sector and industry is XERS in?
Xeris Biopharma Holdings Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Xeris Biopharma Holdings Inc. go public?
Xeris Biopharma Holdings Inc. (XERS) completed its IPO in 2018.What are analysts saying about XERS?
Xeris Biopharma Holdings Inc. has had 8 recent analyst actions on file. The most recent action was from Barclays: Overweight with a $900.00 price target on 2025-12-09. Recent price targets range from $300.00 to $1000.00.What companies are similar to XERS?
Notable peers in the same industry include APLS (Apellis Pharmaceuticals Inc.), RETA (Reata Pharmaceuticals Inc.), SBBP (Strongbridge Biopharma plc). Compare XERS side-by-side with any of them on Quantisnow.How can I track XERS on Quantisnow?
Quantisnow aggregates Xeris Biopharma Holdings Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow XERS to receive live email and push alerts on every new disclosure.